ArticleOrphanet journal of rare diseases2025
Clinical, biochemical and genetic characteristics of patients with argininosuccinate lyase deficiency from a single center cohort in China.
Article in Orphanet journal of rare diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundArgininosuccinate lyase deficiency (ASLD) is a rare autosomal recessive urea cycle disorder (UCD) resulting from mutations in the ASL gene. Previous studies of ASLD in patients from China have predominantly been limited to individual case reports, lacking comprehensive cohort study. This study aimed to systematically evaluate the clinical features, biochemical abnormalities, and genetic mutations of Chinese ASLD patients, thereby enhancing the understanding of the unique characteristics of this population.
methodsWe conducted a retrospective analysis of clinical and genetic data from patients diagnosed with ASLD at Shanghai Xinhua Hospital between January 2011 and May 2024.
resultsThe cohort consisted of 28 Chinese ASLD patients from Xinhua Hospital. The median age of symptom onset was 18 days (range: 2 days to 6 years). Five patients (17.9%) died within the first year, and 87.0% (20/23) of survivors exhibited developmental delay. Citrulline levels were elevated in all patients. 14 out of 16 (87.5%) who underwent platelet testing demonstrated elevated platelet counts. The median blood ammonia level was 172 µmol/L (range: 9-1911 µmol/L). Early-onset cases had significantly higher ammonia levels than late-onset cases ( P < 0.0001). Eight patients underwent liver transplantation, which normalized ammonia levels and liver function but did not prevent developmental delay. Genetic analysis identified 14 novel ASL variants.
conclusionsOur study represents the largest cohort of ASLD patients from China reported to date. Despite active interventions, including liver transplantation, the prognosis remains poor, with a high prevalence of developmental delays. The identification of 14 novel pathogenic variants significantly expands the known mutation spectrum of the ASL gene in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.